This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stephens, B. J. Articles by Von Hoff, D. D. Search for Related Content PubMed PubMed Citation Articles by Stephens, B. J. Articles by Von Hoff, D. D. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Minireview

PRL phosphatases as potential molecular targets in cancer

Departments of ¹ Molecular and Cellular Biology and ² Pharmacology and Toxicology, University of Arizona, Tucson, Arizona and ³ Translational Genomics Research Institute, Phoenix, Arizona

Requests for reprints: Daniel D. Von Hoff, Translational Genomics Research Institute, 445 North Fifth Street, Phoenix, AZ 85004. Phone: 602-358-8327; Fax: 602-343-8484. E-mail: dvh{at}tgen.org

The phosphatase of regenerating liver (PRL) family of phosphatases, consisting of PRL-1, PRL-2, and PRL-3, represents an intriguing group of proteins being validated as biomarkers and therapeutic targets in cancer. Individual PRLs are overexpressed in a variety of cancer cell lines and tissues when compared with their normal counterparts. More importantly, several recent studies have shown that PRL-3 is expressed at higher levels and at a greater frequency in colorectal cancer metastases compared with primary colorectal tumors and normal colon tissue. Ectopic expression of PRLs in nontumorigenic cells can influence proliferation and the migratory and invasive properties of cells, while knockdown of endogenous PRL-3 or PRL-1 in cancerous cells using small interfering RNA can abrogate cell motility and ability to metastasize in a mouse model. However, the exact biological function and cellular substrates of the PRLs remain unclear. This review will discuss what is known about the PRLs, what makes the PRLs possible attractive targets for therapeutic intervention, and the possible future directions in PRL biology and inhibitor identification.